Is Pfizer a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Pfizer Ltd is a good quality company .

Is Pfizer undervalued or overvalued?

The key valuation ratios of Pfizer Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Pfizer share price return in the past 10 years?

Pfizer Ltd share price has appreciated 11.8% annually (CAGR) over the past ten years.

Is Pfizer a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Pfizer Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Pfizer Ltd - Stock Valuation and Financial Performance

Name: Pfizer
Brand: Pfizer

BSE: 500680 | NSE: PFIZER | Pharmaceuticals & Drugs | Small Cap

Place order

Pfizer Share Price

₹5,129.10 -55.45 -1.07%
as on 21-Nov'24 16:59

10 Year X-Ray of Pfizer:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	18.2%	22.8%	22.6%	21.5%	23.2%	20.4%	23.6%	29.8%	27.6%	22.4%	-
Value Creation Index ⓘ	0.4	0.7	0.7	0.6	0.7	0.5	1.1	1.7	1.0	1.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1,853	2,012	1,966	1,969	2,082	2,152	2,239	2,611	2,425	2,193	2,238
Sales YoY Gr.	-	8.6%	-2.3%	0.1%	5.7%	3.4%	4%	16.6%	-7.1%	-9.6%	-
Adj EPS ⓘ	34.3	63.9	52.9	77.7	89.4	106.8	108	133.4	131	119.8	135.1
YoY Gr.	-	86.4%	-17.3%	46.9%	15.1%	19.5%	1.1%	23.5%	-1.8%	-8.5%	-
BVPS (₹) ⓘ	431.3	472.9	528.7	586.5	658.2	742.2	523.1	626.1	701.1	785.9	819.9
Adj Net Profit ⓘ	157	292	242	355	409	489	494	610	599	548	618
Cash Flow from Ops. ⓘ	113	345	329	332	97.8	323	427	667	356	257	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	1.9%	1.1%	-0.7%	-9.6%
Adj EPS ⓘ	14.9%	6%	3.5%	-8.5%
BVPSⓘ	6.9%	3.6%	14.5%	12.1%
Share Price	11.8%	4.4%	0.4%	26.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	11.9	14.1	10.6	13.9	14.4	15.3	17.1	23.2	19.7	16.1	16.8
Op. Profit Mgn % ⓘ	20.6	21.6	17.8	25.5	27.3	26.9	31.8	32.1	33.4	29.2	31.7
Net Profit Mgn % ⓘ	8.5	14.5	12.3	18.1	19.7	22.7	22.1	23.4	24.7	25	27.6
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	143	158	150	162	182	195	194	169	182	208	228
Cash Conv. Cycle ⓘ	20	-1	-10	-40	-27	-4	6	20	23	45	183

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 16.80%

Sales growth has been subdued in last 3 years -0.68%

Net Profit has been subdued in last 3 years 3.52%

Sales growth is not so good in last 4 quarters at -2.36%

Latest Financials - Pfizer Ltd.

	Standalone	Consolidated
TTM EPS (₹)	135.1	30
TTM Sales (₹ Cr.)	2,238	772
BVPS (₹.) ⓘ	819.9	0
Reserves (₹ Cr.) ⓘ	3,705	965
P/BV ⓘ	6.32	0.00
PE ⓘ	38.39	172.97

From the Market
52 Week Low / High (₹)	3977.00 / 6452.85
All Time Low / High (₹)	27.50 / 6452.85
Market Cap (₹ Cr.)	23,718
Equity (₹ Cr.)	45.8
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Pfizer:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Pfizer

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Pfizer

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	1,853	2,012	1,966	1,969	2,082	2,152	2,239	2,611	2,425	2,193
Operating Expenses ⓘ	1,474	1,579	1,616	1,468	1,516	1,579	1,526	1,775	1,616	1,558
Manufacturing Costs	173	164	162	131	143	116	130	138	129	118
Material Costs	650	699	712	678	678	742	734	876	803	730
Employee Cost	236	277	304	314	324	365	361	404	332	348
Other Costs ⓘ	415	439	439	345	370	357	301	358	352	362
Operating Profit ⓘ	379	433	350	501	566	573	712	836	809	635
Operating Profit Margin (%)	20.5%	21.5%	17.8%	25.4%	27.2%	26.6%	31.8%	32.0%	33.4%	29.0%
Other Income ⓘ	72	87	101	114	167	184	81	63	101	181
Interest ⓘ	2	1	2	1	2	11	15	11	13	15
Depreciation ⓘ	131	58	63	66	71	103	109	115	106	62
Exceptional Items ⓘ	-80	10	130	0	0	0	0	0	33	8
Profit Before Tax ⓘ	238	470	517	548	660	642	669	773	824	746
Tax ⓘ	138	165	180	188	231	133	171	160	200	195
Profit After Tax	100	305	337	360	429	509	498	613	624	551
PAT Margin (%)	5.4%	15.2%	17.1%	18.3%	20.6%	23.7%	22.2%	23.5%	25.7%	25.1%
Adjusted EPS (₹)	21.9	66.7	73.6	78.7	93.8	111.3	108.8	133.9	136.4	120.5
Dividend Payout Ratio (%)	57%	23%	27%	25%	24%	297%	32%	22%	51%	29%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	1,973	2,163	2,419	2,683	3,011	3,395	2,393	2,864	3,207	3,596
Share Capital ⓘ	46	46	46	46	46	46	46	46	46	46
Reserves ⓘ	1,927	2,118	2,373	2,637	2,966	3,350	2,347	2,819	3,162	3,550
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	3	3	3	3	3	3	3	3	3	3
Long Term Debt	3	3	0	0	0	0	0	0	0	0
Short Term Debt	0	0	3	3	3	3	3	3	3	3
Trade Payables	334	338	388	496	436	427	284	264	217	166
Others Liabilities ⓘ	237	384	452	509	490	580	573	723	476	411
Total Liabilities ⓘ	2,547	2,888	3,261	3,690	3,940	4,405	3,252	3,854	3,903	4,175
Fixed Assets
Gross Block	1,289	981	983	1,095	1,100	1,277	1,279	1,345	1,352	1,356
Accumulated Depreciation	344	56	116	178	246	335	414	504	603	643
Net Fixed Assetsⓘ	944	925	867	917	854	942	865	841	749	713
CWIP ⓘ	13	3	15	1	0	1	3	1	8	0
Investmentsⓘ	43	0	0	0	0	0	0	0	0	0
Inventories	388	361	322	297	387	431	435	449	418	434
Trade Receivables	160	142	110	155	172	172	109	143	152	188
Cash Equivalents ⓘ	609	1,025	1,523	1,772	1,914	2,220	1,115	1,643	1,860	2,047
Others Assetsⓘ	390	432	423	549	613	640	726	777	717	794
Total Assets ⓘ	2,547	2,888	3,261	3,690	3,940	4,405	3,252	3,854	3,903	4,175

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	113	345	329	332	98	323	427	667	356	257
PBT ⓘ	238	470	517	548	660	642	669	773	824	746
Adjustment ⓘ	61	-20	-154	-33	-79	-54	55	76	-131	-89
Changes in Working Capital ⓘ	-40	69	149	10	-245	-52	-92	44	-34	-246
Tax Paid ⓘ	-145	-174	-183	-194	-238	-213	-204	-226	-303	-154
Cash Flow From Investing Activity ⓘ	-89	-701	-250	-238	35	1,530	-469	-575	-36	54
Capex	-20	53	169	-69	27	-2	-18	-13	-64	34
Net Investments	0	-833	-502	0	0	0	-502	-613	-229	-109
Others ⓘ	-69	79	84	-169	8	1,532	51	51	257	129
Cash Flow From Financing Activityⓘ	-1	-62	-83	-110	-110	-164	-1,571	-181	-346	-235
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	-3	-11	-13	-11
Dividend Paid ⓘ	-1	-50	-69	-92	-91	-103	-1,519	-160	-297	-183
Others ⓘ	0	-12	-14	-19	-19	-60	-49	-10	-35	-41
Net Cash Flow ⓘ	23	-417	-3	-17	23	1,690	-1,613	-88	-26	75

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	7.63	14.75	14.7	14.11	15.07	15.89	17.19	23.3	20.55	16.21
ROCE (%)	18.19	22.78	22.62	21.49	23.22	20.38	23.62	29.78	27.56	22.37
Asset Turnover Ratio	1.1	0.77	0.66	0.57	0.55	0.52	0.58	0.76	0.66	0.57
PAT to CFO Conversion(x)	1.13	1.13	0.98	0.92	0.23	0.63	0.86	1.09	0.57	0.47
Working Capital Days
Receivable Days	32	26	23	24	29	29	23	17	21	27
Inventory Days	51	65	61	57	60	69	71	59	62	67
Payable Days	139	176	186	238	251	212	177	114	109	96

Pfizer Ltd Stock News

Pfizer Ltd FAQs

What is the share price of Pfizer?

Company share prices are keep on changing according to the market conditions. The closing price of Pfizer on 21-Nov-2024 16:59 is ₹5,129.1.

What is the market cap of Pfizer?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Pfizer stood at ₹23,718.1.

What is the P/E ratio of Pfizer?

The latest P/E ratio of Pfizer as of 21-Nov-2024 16:59 is 38.39.

What is the P/B ratio of Pfizer?

The latest P/B ratio of Pfizer as of 21-Nov-2024 16:59 is 6.32.

What is the 52-week high and low of Pfizer?

The 52-week high of Pfizer is ₹6,452.9 and the 52-week low is ₹3,977.

What is the TTM revenue of Pfizer?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Pfizer is ₹2,238 ( Cr.) .

About Pfizer Ltd

Pfizer is a Public Limited Company, incorporated under the Indian Companies Act, 1913, having its registered office in Mumbai, Maharashtra and is listed on the BSE Limited and the National Stock Exchange of India Limited

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. The company is taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.

Business area of the company

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Awards

2001

OPPI Brand Excellence Award for Minipress XL.

2002

Express Pharma Biz Award for overall performance.
Rated as one of India's most socially responsive companies. Awarded by FICCI-Socio Economic Development Foundation for our Social Responsiveness.

2003

Voted as the 5 'Most Respected Company' in the Pharma sector (Business World).
Corporate Advertising Campaign won a Silver Award at the ABBY-All India Awards for Creative Excellence. Gelusil brand received a Silver Award for printing advertising.
Golden Peacock National Training Special Commendation for Training practices.

2004

Ranked 5 among all pharmaceutical companies, with respect to corporate image, field-force, and promotional programs (AC Nielsen-ORG Marg 'Corporate Image Survey').
Ranked 1 among all Pharma MNCs & 4 among all Pharma Companies by Business World.
Kewal Handa, CFO Pfizer Limited receives the ‘India CFO 2004 - Excellence in Finance in an MNC’ by International Market - Assessment Group.

2005

Golden Peacock Innovative Service Award for Prime MD Today (Daxid).
PC Quest 'Best IT Implementation Users Choice' award for OPTILEARN.
Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
Ranked 1 among multinationals and #3 among all pharmaceuticals, in the Business World survey.

2006

Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
Ranked 1 among multinationals and 3 among all pharmaceuticals, in the Business World survey.
Kewal Handa, Managing Director Pfizer, awarded the Bharat Shiromani award for his outstanding contribution in the pharmaceutical industry.

2007

Reader’s Digest Trusted Brand Asia - Gold Award 2007’ in the vitamin and health supplement category for Becosules.

2008

Frost & Sullivan Brand Strategy Leadership Award for Becosules in the Indian Dietary Supplement Market.
Pfizer India was recently conferred the ‘Innovative Training Practices’ Award for promoting effective and optimum utilization of human resource through education and training by the Indian Society for Training and Development (ISTD).

2009

Pfizer Limited (India) conferred the Multinational Pharmaceutical Company of the Year by Frost & Sullivan.

2010

Pfizer Limited awarded the Most Admired Pharmaceutical Company of the Year by Pharma Leaders Magazine.
Kewal Handa, Country Manager - Pfizer Limited recognized as Pharma Professional of the Year by Pharma Leaders Magazine.
Pfizer wins the Community Engagement Award at the Asia Responsible Entrepreneurship Awards 2010 in India.

2011

Pfizer India has been recognized as one of The Best Companies to Work For by Business Today magazine.

2012

J.D. Power and Associates has honored the MS LifeLines call center with certification for an outstanding customer service experience. This is the first time J.D. Power has recognized a pharmaceutical call center. Click Here.

2013

GBCHealth Business Leadership Award - in recognition for the Global Health Fellows program. This award is given annually to a company or business leader with a deep and long-term commitment to global health that extends beyond the business objective of the company itself. Caroline Roan will be accepting the award on behalf of Pfizer.
Business Action on Health Award in Application of Core Competence for Global Health Fellows Program (commendation). Oonagh Puglisi will be accepting the award for the GHF program.
Business Action on Health Award in Partnership/Collective Action for Advancing Cancer & Tobacco Control in China Program. Danlong Feng, Corporate Affairs Director, Pfe China, will be accepting the award.
QUESTAR Award - The International Awards Festival for Excellence in Video Communications Pfizer was awarded the Grand -- best of category -- in Annual Reports in the 2013 Questar Awards.
Telly Award - For over a quarter century, the Telly statuette has been a symbol of creative excellence. Pfizer was awarded - Bronze at the 2013 Telly's for online videos.

Milestones:

1849: Charles Pfizer & Company established. 1' product for treatment of intestinal worms is a success.
1880: Pfizer manufactures Citric Acid. Rapid growth on the back of aerated drinks demand.
1882: Alexander Fleming discovers penicillin.
1944: Pfizer finds a way to mass-produce Penicillin.
1950: Terramycin, the 1st pharmaceutical sold in the US under the Pfizer label.
1950: India operation launched, with HQ in Mumbai.
1966: Pfizer listed on the Bombay Stock Exchange.
1989: Dolonex (Feldene) launched in India.
1993: Amlogard (Norvasc) launched in India.
1996: Launch of MinipressXL, an anti hypertensive drug.
1998: Launch of Viagra, for erectile dysfunction.
1999: Pfizer listed on the National Stock Exchange.
2000: Launch of Magna& a unique hospital antibiotic.
2002: Futuristic tablet manufacturing Goa plant commissioned in a record 13 months.
2003 Completes merger with Parke-Davis (India) Ltd.
2005: Announces merger with Pharmacia Healthcare ltd.
2006: Launch of LYRICA (pregaballn for treatment of neuropathic pain)
2008: Launch of Champix - a non-nicotine smoking cessation prescription drug.
2010: Launch of Prevenar 13, vaccine for prevention of pneumococcal disease and included later in India’s Universal Immunization Programe.
2015: Completed merger with Wyeth Limited.
2016: Launched Xeljanz-the first oral Janus Kinase (JAK) inhibitor.
2017: Acquires 2 breakthrough brands- Meronem, Neksium.
2019: Reorganizes into 3 distinct business units: Pfizer Biopharma Group, UpJohn and Consumer Healthcare. New purpose and values unveiled.
2019: Launches novel anti-bacterial Zavicefta in India.
2020: Launch of Zinforo, a noval cephalosporin indicated for treatment of adult patients with community- acquired Pneumonia.